Compare Stocks: APGE, BIIB, INSM, and ALNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$221.20 +1.9%	$277.25	$197.81 ▼ $495.55	$29.03B	0.3	2.20 million shs	1.44 million shs
APGE Apogee Therapeutics	$134.69 +0.0%	$121.58	$34.58 ▼ $134.88	$8.33B	0.35	1.18 million shs	1.06 million shs
BIIB Biogen	$203.89 -1.6%	$202.93	$128.25 ▼ $219.72	$30.60B	0.17	1.27 million shs	936,828 shs
INSM Insmed	$132.57 -1.6%	$106.29	$90.39 ▼ $212.75	$29.43B	0.81	3.21 million shs	2.73 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.94%	+1.01%	-25.96%	-24.11%	-49.15%
APGE Apogee Therapeutics	+0.03%	+0.37%	+0.78%	+60.46%	+288.72%
BIIB Biogen	-1.56%	-2.19%	+2.38%	-0.31%	+59.29%
INSM Insmed	-1.62%	+34.25%	+14.67%	+12.36%	+17.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$221.20 +1.9%	$277.25	$197.81 ▼ $495.55	$29.03B	0.3	2.20 million shs	1.44 million shs
APGE Apogee Therapeutics	$134.69 +0.0%	$121.58	$34.58 ▼ $134.88	$8.33B	0.35	1.18 million shs	1.06 million shs
BIIB Biogen	$203.89 -1.6%	$202.93	$128.25 ▼ $219.72	$30.60B	0.17	1.27 million shs	936,828 shs
INSM Insmed	$132.57 -1.6%	$106.29	$90.39 ▼ $212.75	$29.43B	0.81	3.21 million shs	2.73 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.94%	+1.01%	-25.96%	-24.11%	-49.15%
APGE Apogee Therapeutics	+0.03%	+0.37%	+0.78%	+60.46%	+288.72%
BIIB Biogen	-1.56%	-2.19%	+2.38%	-0.31%	+59.29%
INSM Insmed	-1.62%	+34.25%	+14.67%	+12.36%	+17.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$396.72	79.35% Upside
APGE Apogee Therapeutics	2.24	Hold	$121.25	-9.97% Downside
BIIB Biogen	2.56	Moderate Buy	$224.61	10.16% Upside
INSM Insmed	3.00	Buy	$205.52	55.03% Upside

Current Analyst Ratings Breakdown

Latest APGE, BIIB, INSM, and ALNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00 ➝ $195.00
8/10/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$179.00 ➝ $175.00
8/7/2026	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$218.00
8/7/2026	INSM Insmed	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$170.00
8/7/2026	INSM Insmed	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$207.00 ➝ $205.00
8/7/2026	INSM Insmed	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$172.00
8/7/2026	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$161.00 ➝ $169.00
8/6/2026	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$175.00
8/4/2026	ALNY Alnylam Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$410.00 ➝ $315.00
8/4/2026	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$221.00 ➝ $241.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	7.97	$2.85 per share	77.60	$10.12 per share	21.86
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
BIIB Biogen	$9.89B	3.05	$22.28 per share	9.15	$127.56 per share	1.60
INSM Insmed	$606.42M	47.74	N/A	N/A	$3.47 per share	38.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	41.12	22.92	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-32.16%	-30.91%	N/A
BIIB Biogen	$1.29B	$5.65	36.09	12.44	6.40	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	63.43	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)

Latest APGE, BIIB, INSM, and ALNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
APGE Apogee Therapeutics	N/A	32.59	32.59
BIIB Biogen	0.39	1.87	1.26
INSM Insmed	0.74	3.72	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
APGE Apogee Therapeutics	79.04%
BIIB Biogen	87.93%
INSM Insmed	N/A

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
APGE Apogee Therapeutics	24.30%
BIIB Biogen	0.25%
INSM Insmed	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
APGE Apogee Therapeutics	91	61.88 million	46.84 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable

APGE, BIIB, INSM, and ALNY Headlines

Recent News About These Companies

JPMorgan Chase & Co. Has Lowered Expectations for Insmed (NASDAQ:INSM) Stock Price

23 minutes ago | americanbankingnews.com

Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co.

August 10 at 3:17 PM | marketbeat.com

Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM

August 10 at 5:03 AM | marketbeat.com

Assenagon Asset Management S.A. Acquires 155,011 Shares of Insmed, Inc. $INSM

August 10 at 3:11 AM | marketbeat.com

Insmed (NASDAQ:INSM) Posts Earnings Results

August 8, 2026 | marketbeat.com

Insmed Shares Rise After Raising FY26 Guidance for Products

August 8, 2026 | marketwatch.com

Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM)

August 8, 2026 | americanbankingnews.com

Insmed (NASDAQ:INSM) Shares Gap Up on Earnings Beat

August 8, 2026 | americanbankingnews.com

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

August 7, 2026 | zacks.com

Quantinno Capital Management LP Grows Stock Holdings in Insmed, Inc. $INSM

August 7, 2026 | marketbeat.com

Insmed catapults 34%, leading a biotech rally but Mirum takes a bath

August 6, 2026 | msn.com

Insmed catapults 30%, leading a biotech rally; but Mirum takes a bath

August 6, 2026 | msn.com

Insmed raises BRINSUPRI revenue guidance after strong Q2 growth and expands peak sales outlook

August 6, 2026 | msn.com

Insmed Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Insmed Sees Unusually Large Options Volume (NASDAQ:INSM)

August 6, 2026 | marketbeat.com

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

August 6, 2026 | zacks.com

Insmed (NASDAQ:INSM) Shares Gap Up After Better-Than-Expected Earnings

August 6, 2026 | marketbeat.com

Insmed: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2026 | zacks.com

Insmed Incorporated 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APGE, BIIB, INSM, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$221.20 +4.22 (+1.94%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$221.48 +0.28 (+0.12%)

As of 08/11/2026 07:56 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Apogee Therapeutics NASDAQ:APGE

$134.69 +0.04 (+0.03%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$134.78 +0.09 (+0.07%)

As of 08/11/2026 07:34 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Biogen NASDAQ:BIIB

$203.89 -3.24 (-1.56%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$203.43 -0.46 (-0.23%)

As of 08/11/2026 07:34 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insmed NASDAQ:INSM

$132.57 -2.18 (-1.62%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$132.13 -0.44 (-0.33%)

As of 08/11/2026 07:59 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APGE, BIIB, INSM, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APGE, BIIB, INSM, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APGE, BIIB, INSM, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APGE, BIIB, INSM, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Apogee Therapeutics NASDAQ:APGE

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APGE, BIIB, INSM, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APGE, BIIB, INSM, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APGE, BIIB, INSM, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APGE, BIIB, INSM, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Apogee Therapeutics NASDAQ:APGE

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools